Variables | HR | 95% CI | P-value | Overall P-value |
---|---|---|---|---|
Age | Â | Â | Â | Â |
   ≤ 40 | 1.51 | 1.03 – 2.23 | 0.0352 |  |
   > 40 | 1 | – | – |  |
Node Status | Â | Â | < 0.0001 | Â |
   Positive | 2.24 | 1.53 – 3.29 |  |  |
   Negative | 1 | – |  |  |
Tumor Size | Â | Â | Â | 0.0170 |
   ≤ 2 | 1 | – | - |  |
   3 – 5 | 1.28 | 0.85 – 1.92 | 0.2440 |  |
   > 5 | 2.23 | 1.20 – 4.36 | 0.0118 |  |
Stage | Â | Â | Â | 0.0002 |
   I | 0.55 | 0.35 – 0.86 | 0.0093 |  |
   II | 0.44 | 0.22 – 0.87 | 0.0195 |  |
   III | 1 | -- | - |  |
Grade | Â | Â | Â | 0.0078 |
   I | 1 | -- | -- |  |
   II | 0.95 | 0.55 – 1.64 | 0.8550 |  |
   III | 1.21 | 0.69 – 2.13 | 0.4978 |  |
Lymph-Vascular Invasion | Â | Â | Â | Â |
   Both Positive | 1.11 | 0.78 – 1.58 | 0.5708 |  |
   Both Negative | 1 | -- | -- |  |
Hormonal Receptor Status | Â | Â | Â | 0.0027 |
   ER+ PR+ | 1 | -- | -- |  |
   ER- PR- | 1.21 | 0.79 – 1.83 | 0.3786 |  |
   ER+ PR- | 1.17 | 0.60 – 2.29 | 0.6390 |  |
   ER- PR+ | 1.79 | 1.11 – 2.89 | 0.0179 |  |